Artiva Biotherapeutics (ARTV) Stock Price, News & Analysis

Company Overview

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $1.67 to $1.90
• 50-Day Range: $1.68 to $2.47
• 52-Week Range: $1.67 to $17.31
• Volume: 324,628 shs
• Average Volume: 170,559 shs
• Market Capitalization: $40.92 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.80
• Consensus Rating: Buy

Artiva Biotherapeutics Stock Analysis - MarketRank™

Artiva Biotherapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 397th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Artiva Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Artiva Biotherapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Artiva Biotherapeutics are expected to grow in the coming year, from ($4.95) to ($2.83) per share.

Price to Book Value per Share Ratio

Artiva Biotherapeutics has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ARTV.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Artiva Biotherapeutics does not currently pay a dividend.

Dividend Growth

Artiva Biotherapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for ARTV.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.98

News Sentiment

Artiva Biotherapeutics has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Artiva Biotherapeutics this week, compared to 1 article on an average week.

Search Interest

8 people have searched for ARTV on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Artiva Biotherapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

21.40% of the stock of Artiva Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

ARTV Stock Analysis - Frequently Asked Questions

How have ARTV shares performed this year?

Artiva Biotherapeutics' stock was trading at $10.08 at the beginning of the year. Since then, ARTV stock has decreased by 83.3% and is now trading at $1.68.
View the best growth stocks for 2025 here.

How were Artiva Biotherapeutics' earnings last quarter?

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) issued its earnings results on Thursday, May, 8th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by $0.15.

When did Artiva Biotherapeutics IPO?

Artiva Biotherapeutics (ARTV) raised $167 million in an IPO on Friday, July 19th 2024. The company issued 13,920,000 shares at a price of $12.00 per share.

Who are Artiva Biotherapeutics' major shareholders?

Artiva Biotherapeutics' top institutional investors include venBio Partners LLC (4.92%), Charles Schwab Investment Management Inc. (0.23%) and Nuveen LLC (0.20%). Insiders that own company stock include Yong-Jun Huh and Global Strategic Fund I Venbio.
View institutional ownership trends.

How do I buy shares of Artiva Biotherapeutics?

Shares of ARTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Artiva Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Artiva Biotherapeutics investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Delcath Systems (DCTH), Advanced Micro Devices (AMD), AngioDynamics (ANGO), Broadcom (AVGO) and Genius Sports (GENI).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 6/19/2025
• Next Earnings (Estimated): 6/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ARTV
• Previous Symbol: NASDAQ:ARTV
• CIK: 1817241
• Web: www.artivabio.com
• Phone: (858) 267-4467
• Fax: N/A
• Employees: 81
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $17.80
• High Stock Price Target: $21.00
• Low Stock Price Target: $12.00
• Potential Upside/Downside: +959.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$65.37 million
• Net Margins: N/A
• Pretax Margin: -26,045.02%
• Return on Equity: -75.95%
• Return on Assets: -39.51%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.93
• Quick Ratio: 13.93

Sales & Book Value

• Annual Sales: $250 thousand
• Price / Sales: 163.70
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.68 per share
• Price / Book: 0.22

Miscellaneous

• Outstanding Shares: 24,360,000
• Free Float: 19,149,000
• Market Cap: $40.92 million
• Optionable: N/A
• Beta: N/A